American Association for Cancer Research
Browse
- No file added yet -

Supplementary Figure 7 from In vivo Imaging of Inflammation- and Tumor-Induced Lymph Node Lymphangiogenesis by Immuno–Positron Emission Tomography

Download (1.98 MB)
journal contribution
posted on 2023-03-30, 20:05 authored by Viviane Mumprecht, Michael Honer, Benjamin Vigl, Steven T. Proulx, Eveline Trachsel, Manuela Kaspar, Nadja E. Banziger-Tobler, Roger Schibli, Dario Neri, Michael Detmar
Supplementary Figure 7 from In vivo Imaging of Inflammation- and Tumor-Induced Lymph Node Lymphangiogenesis by Immuno–Positron Emission Tomography

History

ARTICLE ABSTRACT

Metastasis to regional lymph nodes (LN) is a prognostic indicator for cancer progression. There is a great demand for sensitive and noninvasive methods to detect metastasis to LNs. Whereas conventional in vivo imaging approaches have focused on the detection of cancer cells, lymphangiogenesis within tumor-draining LNs might be the earliest sign of metastasis. In mouse models of LN lymphangiogenesis, we found that systemically injected antibodies to lymphatic epitopes accumulated in the lymphatic vasculature in tissues and LNs. Using a 124I-labeled antibody against the lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1), we imaged, for the first time, inflammation- and tumor-draining LNs with expanded lymphatic networks in vivo by positron emission tomography (PET). Anti-LYVE-1 immuno-PET enabled visualization of lymphatic vessel expansion in LNs bearing metastases that were not detected by [18F]fluorodeoxyglucose-PET, which is clinically applied to detect cancer metastases. Immuno-PET with lymphatic-specific antibodies may open up new avenues for the early detection of metastasis, and the images obtained might be used as biomarkers for the progression of diseases associated with lymphangiogenesis. Cancer Res; 70(21); 8842–51. ©2010 AACR.